

Press Release



For Immediate Release

1st October 2003

For further information please contact:

NP PHARM

Patrick R. Sanial

Tel: +33 (0)1 34 87 78 97

NP PHARM Doubles its Production Potential at Bazainville

New Capacity will enable NP Pharm to meet the Increased Market Demand, in particular the U.S.A.

Paris, France...NP Pharm, one of the world leaders in the production of innovative excipients for DDS products, announces the extension of its production site at Bazainville, near Paris. The facility is committed exclusively to the production of sugar spheres, Suglets® for pharmaceutical companies. The extension of the site will increase the manufacturing capacity by 50% which will permit a yearly production of 800 tons, thus enhancing NP Pharm's future growth strategy, particularly in the North American market.

The new facility which has been operational since early July, is cGMP compliant, certified ISO 9001 version 2000, covers an area of 2000 square meters consisting of a production area and a warehouse area. Furthermore, the Company is in the process of recruiting 3 more production operators. All of which will enable NP Pharm to boost its production for its major Clients on key markets in North America and China.

Since its creation in 1992, NP Pharm has acquired a solid know-how in the use of pharmaceutical excipients used for oral delivery products, which today is the largest market segment. NP Pharm is specialized in the production of sugar spheres used as components for controlled release drug delivery technologies, to which the active substance and a binding agent are added.

NP Pharm has three patented products : Suglets®, Nptab®, and Ethispheres®, sold to the world's most renowned pharmaceutical laboratories. These product lines are made to measure in conformity with the requirements of the pharmaceutical industry, and are in strict conformity with Good Manufacturing Practice, ensuring correct quality assurance standards, manufacturing methods and reproducibility.

"The expansion of our plant is further evidence of the growth that we expect NP PHARM to achieve over the next few years, particularly in North America and in China. With the demand for oral modified release products increasing rapidly, it is important that we position ourselves in order to meet the anticipated demand from our partners. It is also very gratifying to be able to create additional employment", comments Patrick R. Sanial, NP PHARM Managing Director.